Erratum to reply to “successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients—A Czech multicenter experience”: A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2024-04-25 DOI:10.1002/hon.3267

引用次数: 0

Abstract

Cassin R, Rampi N, Fidanza C, et al. Reply to “successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients—A Czech multicenter experience”: A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era. Hematol Oncol. 2023; 41 (1):213-217. https://doi.org/10.1002/hon.3079.

In the article, the first name of the third author was abbreviated. The correct author name is Cecilia Anna Fidanza instead of Fidanza C.

We apologize for this error.

查看原文本刊更多论文

抗SARS-CoV-2单克隆中和抗体在SARS-CoV-2感染的血液病患者中的成功早期应用--捷克多中心经验》的勘误回复：索托维单抗时代的SARS-CoV-2 Omicron感染和侵袭性淋巴瘤病例系列

Cassin R, Rampi N, Fidanza C, et al. 对 "在SARS-CoV-2感染的血液病患者中早期成功使用抗SARS-CoV-2单克隆中和抗体--捷克多中心经验 "的回复：索特维单抗时代的SARS-CoV-2 Omicron感染和侵袭性淋巴瘤病例系列。Hematol Oncol.2023; 41 (1):213-217. https://doi.org/10.1002/hon.3079.In 文章中，第三作者的名字被缩写。正确的作者姓名是Cecilia Anna Fidanza，而不是Fidanza C.我们对此错误深表歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.